Abstract
Background
Health care planning demands a detailed knowledge of the course of chronic diseases in the Irish population. This study describes hospital admission rates, medication use and outcomes in a large cohort of patients with ulcerative colitis attending a tertiary referral centre in Ireland.
Method
Four hundred and twenty-four patients who attended during the 18-year period from January 1991 to January 2009 were identified. Baseline demographics, hospital admission, medications required, extent of colitis and date of colectomy were recorded.
Results
More than half (55.4%) of the patients were managed exclusively in an outpatient setting throughout diagnosis and follow-up. Systemic corticosteroids, thiopurines and infliximab were required by 70, 29.5 and 5% of the patients, respectively. Overall 5-year colectomy rate due to failure of medical therapy was 15.8%. Independent predictors of colectomy were hospital admission at first presentation (odds ratio 3.6, p < 0.0001) and pancolitis at diagnosis (odds ratio 2.3, p < 0.01).
Conclusions
The majority of patients with colitis have an uncomplicated disease course and do not require thiopurines, biologic agents or hospital admission. Principal management at a primary care level may be appropriate in many cases. Colectomy rates at a specialist centre in Ireland compare favourably with international figures.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bernstein CN, Shanahan F (2008) Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel disorders. Gut 57:1185–1191
Rampton DS, Shanahan F (2008) Fast facts: inflammatory bowel disease, 3rd edn. Health Press Limited, Oxford
Targan S, Shanahan F, Karp LC (2010) Inflammatory bowel disease: translating basic science into clinical practice. Wiley-Blackwell, Chichester
Strange EF, Travis SPL, Vermeire S et al (2008) European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn’s Colitis 2:1–23
Travis SPL, Strange EF, Lemann M et al (2008) European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn’s Colitis 2:24–62
Hoie O, Wolters FL, Riis L et al (2007) Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 132:507–515
Henrikson M, Jahnson J, Lygren I et al (2006) Ulcerative colitis and clinical course: results of a 5-year population based follow-up study (the IBSEN study). Inflamm Bowel Dis 12:543–550
Langholtz E, Munkholm P, Nielson OH, Kreiner S, Binder V (1991) Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 26:1247–1256
Dinesen LC, Walsh AJ, Nedeljkovic-Protic M et al (2010) The pattern and outcome of acute severe colitis. J Crohn’s Colitis 4:431–437
Aratari A, Papi C, Clemente V et al (2008) Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis 40:821–826
Robinson A, Thompson G, Wilkin D et al (2001) Guided self-management and patient directed follow-up of ulcerative colitis: a randomised trial. Lancet 358:976–981
Robinson A (2004) Review article: inflammatory bowel disease—empowering the patient and improving outcome. Aliment Pharm Ther 20(suppl 4):84–87
Ho GT, Chiam P, Drummond H, Loane J, Arnott IDR, Satsangi J (2006) The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 24:319–330
Jakobsen C, Munkholm P, Paerregaard A, Wewer V (2011) Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators—a population-based study. Inflamm Bowel Dis 17:1731–1740
Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ (2001) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121:255–260
Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M (2007) Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 46:187–208
Kim DU, Kim YH, Kim BJ et al (2009) The efficacy of low dose azathioprine/6-mercaptopurine in patients with inflammatory bowel disease. Hepatogastroenterology 56:1395–1402
Scribano ML (2008) Adverse events of IBD therapies. Inflamm Bowel Dis 14(suppl 2):S210–S211
Acknowledgments
The authors are supported in part by Science Foundation Ireland. They also gratefully acknowledge the lessons that they have learned participating in the care of their patients.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Desmond, A.N., Shanahan, F. Managing chronic disease in Ireland: hospital admission rates and clinical outcomes in a large ulcerative colitis population. Ir J Med Sci 181, 65–71 (2012). https://doi.org/10.1007/s11845-011-0760-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-011-0760-y